Can people with Parkinson's disease take rasagiline?

Rasagiline (English namerasagiline) is a second-generation monoamine oxidase inhibitor that blocks the breakdown of the neurotransmitter dopamine. Compared with the first-generation monoamine oxidase inhibitors, its inhibitory effect is 5 to 10 times stronger. For patients whose long-term use of dopa preparations has declined, rasagiline can also improve their efficacy. More importantly, in addition to relieving symptoms, it also has a certain neuroprotective effect.

Based on clinical trials and practical applications, rasagiline is not particularly toxic to humans and is therefore suitable for the treatment of primary Parkinson's syndrome. It can be used as a first-line drug for the early treatment of Parkinson's disease (PD), or used in combination with levodopa (levodopa) to treat moderate and severe Parkinson's disease.

However, rasagiline may also have some adverse reactions during treatment. These reactions include, but are not limited to, nausea, vomiting, dizziness, headache, insomnia, dreaminess, depression, anxiety, etc. In addition, side effects such as movement disorders, muscle stiffness, bradykinesia, akathisia, and insomnia may occur. These side effects may have an impact on the patient's quality of life.

Therefore, whether patients with Parkinson's disease can take rasagiline requires comprehensive consideration of the patient's specific conditions. In general, rasagiline may be considered if a patient's condition is appropriate and the doctor believes the potential benefits outweigh the possible risks. However, if patients experience serious adverse reactions, they should seek medical treatment promptly and adjust or change medications under the guidance of a doctor.